Denali Therapeutics Inc.
tividenofusp alfa
Hunter syndrome
Resolved
93days ago
FDA decision · Apr 5, 2026
What's at stake
The FDA's approval decision on tividenofusp alfa for Hunter syndrome is due Apr 5, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 17h ago
“PDUFA target action date of April 5, 2026”